Adamax
Marketed as a Semax-like peptide for focus and memory; its chemical identity and effects are not established in published research.
What it is
Unknown. No peer-reviewed study of Adamax was found. New Zealand's medicines regulator notes that ACTH-analogue products of this kind make cognitive claims while their mechanism of action is often unknown.
What it is studied for
No published studies of Adamax were found. It is marketed as a cognitive enhancer, and Medsafe reported ACTH-analogue peptides being imported into New Zealand by individuals.
What the evidence says
No peer-reviewed research found
Its identity and effects are not established in the published literature, and Semax findings cannot be assumed to apply to it. Medsafe notes limited clinical research on ACTH analogues and that little is known about their side effects or long-term effects.
How it was studied
No route of use, including the nasal spray form, has been studied in published research.
Regulatory status
No approved use; its identity and effects are not established in the published literature. In June 2025, New Zealand's Medsafe named Adamax and Semax as ACTH analogues and recommended classifying such analogues as prescription medicines.
Where to find it
Brain Power
- Nasal spray Adamax 10 mg per 10 mL bottle
Sold by USA Standard Research, the team behind PeptidesGenie, for research use only. Not for human or veterinary use.
Sources
- 1PubMed search for Adamax research (searched 2026-10-27) Literature search
- 2PubChem: Adamax, Substance SID 513899171 (vendor-deposited) Vendor-supplied database entry
- 3Medsafe (2025): Classification of Unscheduled Peptides, submission to the Medicines Classification Committee Regulator classification submission
Source-checked · 27 Oct 2026